Cannabis: The Effects on Patients With Respiratory Conditions
Price: FREE for members and non-members
Session recorded on May 21, 2020
Speaker: William Silvers, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this podcast, the participant should be able to:
- Describe the spectrum and prevalence of allergic reactions to Cannabis (“Marijuana”)
- Discuss better communication, non-judgmental, between patients and physicians
- Update on diagnosis, management, and benefits/harms of cannabis
All identified conflicts of interest have been resolved.
Sally Schlosser, RN, Planner, Reviewer
Nothing to disclose
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
William Silvers, MD, Speaker
Nothing to disclose
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance